DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20172756

A case report of ofloxacin induced fixed drug eruptions and hypersensitivity reaction

Ashraffunnissa Fatima Farheen Kamal, Shrenik H. Vardhamane, Amreen Saba

Abstract


Ofloxacin is the most commonly used first generation fluoroquinolones. Its activity against gram negative organisms lie between Norfloxacin and Ciprofloxacin. It is used for treating infections like UTI, gastroenteritis etc. It is generally well tolerated, gastric upset is the most common adverse effect. However very few cases of Fixed Drug Eruptions have been reported. Here we report a case of a 16year old female patient who developed redness and rashes all over body along with nausea, vomiting, dizziness, palpitations, blurring of vision, headache and loss of consciousness after receiving Tab ofloxacin 200mg for gastroenteritis. Signs and symptoms subsided within 24 hrs after the drug was stopped and supportive treatment like IV fluids along with dexamethasone was given. Ofloxacin was strongly suspected as the causal drug for the hypersensitivity reaction as the subject had a history of allergic reaction to the same in the past. Early detection of cutaneous lesions and immediate withdrawal of the offending drug can prevent progression of such reactions to their severe variants as well as morbidity and mortality.


Keywords


Fixed drug eruptions, Hypersensitivity reaction, Ofloxacin

Full Text:

PDF

References


Smythe MA, Rybak MJ. Ofloxacin: a review. Drug Intell Clin Pharm. 1989;23:839-46.

Kaur I, Jindal S, Grover IS. Cutaneous Adverse Drug Reaction with Ofloxacin. J Pharmacovigilance. 2014;2:144.

Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137:765-70.

Butler DF. Fixed Drug Eruptions. Available at: http://emedicine.medscape.com/article/1336702-overview. Accessed 9 January 2016

Boopathy D, Prakash M, Mathew B. Method development and validation of simultaneous determination of Ofloxacin and Satranidazole in pharmaceutical dosage form by RP-HPLC. Der Pharmacia Letter. 2010;2(2):22(6).

Tanne JH. FDA adds- black box warning label to fluoroquinolone antibiotics. BMJ. 2008;337(7662):135.

Nordlund JJ, Boissy RE, Hearing VJ, King RA, Portonne J. The Pigmentary System: Physiology and Pathophysiology. New York: Oxford Univ. Press; 1998.

Ozkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges. Nov 2008;6:181-8 (PubMed).

Shiohara T, Mizukawa Y. Fixed Drug Eruption: Easily Overlooked but Needing New Respect. Dermatology. 2002;205:103-4 (PubMed).

Wolff K, Johnson RA, Suurmond D, editors. Fitzpatrick's color atlas and synopsis of clinical dermatology. 5th Ed. New York: McGraw Hill; 2005:20:556-558.

Barnhill RL, Crowson AN. Textbook of dermatopathology. 2nd Ed. New York: McGraw Hill; 2004:8:179.

Scherer K, Bircher AJ. Hypersensitivity reactions to fluoroquinolones. Curr Allergy Asthma. Rep. 2005;5:15-21 (PubMed).

Dhar S, Sharma VK. Fixed drug eruption due to ciprofloxacin. British J of Der. 1996;134:156-8 (PubMed).

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics. 1981;30:239‑45.

The use of WHO‑UMC system for standardized case causality assessment. Available at: http://www.WHO‑UMC.org/graphics/4409.pdf